Kairos Pharma, Ltd.
KAPA
$0.85
-$0.01-1.05%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.52% | -462.06% | -290.71% | 12.34% | -235.58% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 1,050.00% |
| Total Other Non-Cash Items | 27.85% | 6,975.00% | 280.00% | -127.71% | -- |
| Change in Net Operating Assets | 87.64% | -3,169.23% | 44.48% | -397.56% | -581.30% |
| Cash from Operations | 58.51% | -379.17% | -2,083.33% | -2,831.82% | -2,319.78% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 8,347.50% | 118.63% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -100.00% | 3,535.96% | 100.00% | -55.36% |
| Cash from Financing | -35.22% | 49.66% | 3,535.96% | -97.22% | 2,428.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.49% | -2,963.16% | 4,522.64% | -32,316.67% | 2,503.01% |